EXPERIMENTAL streptomycin in treatment of intraocular infections have been published.1 Since, as has been shown by Leopold and Nichols,1a streptomycin penetrates poorly from the blood stream into the normal vitreous humor, systemic administration of the drug is inadequate in therapy of infections of the vitreous. In a more recent series of experiments,1b Leopold demonstrated that streptomycin given by direct intravitreal, retrobulbar injection plus iontophoresis, or by irrigations of the anterior chamber reduced the severity of experimental infections of the vitreous due to Escherichia coli. These methods were effective in the order noted. The report further indicated that direct intravitreal injections of streptomycin produced retinochoroidal exudation and subsequent degeneration, but that in concentrations below 800 micrograms per injection the damage was minimal and was limited to the site of injection. Studies of retention of streptomycin in the vitreous1e indicated that after a single intraocular injection of 100 micrograms
SHOEMAKER RE. INTRAVITREAL USE OF STREPTOMYCIN. Arch Ophthalmol. 1949;41(5):629–632. doi:10.1001/archopht.1949.00900040645012
Customize your JAMA Network experience by selecting one or more topics from the list below.